乳腺癌患者BRCA1启动子甲基化与生存时间关系的Meta分析

Meta-analysis of the Relationship Between the BRCA1 Promoter Methylation and Survival Time in Patients With Breast Cancer

目的讨论乳腺癌患者BRCA1启动子甲基化与患者生存时间的关系。方法从Pub Med和中国生物医学文献数据库(CBM)等中英文专业数据库中收录的从建库至2017-11的有关乳腺癌患者BRCA1启动子甲基化的相关文献,采用Stata 12.0软件对数据进行Meta分析,合并值为风险比(HR)及其95%CI。结果共纳入13篇文献,共计3 654例患者。Meta分析结果显示:BRCA1启动子甲基化阴性患者与阳性患者相比,单因素分析的总生存时间合并结果为HR=1.91,95%CI(1.25~2.57);多因素分析的总生存时间合并结果为HR=1.50,95%CI(1.09~1.90);单因素分析的无病生存时间合并结果为HR=2.08,95%CI(1.48~2.68);多因素分析的无病生存时间合并结果为HR=2.69,95%CI(0.39~5.00)。结论 BRCA1蛋白表达可能是影响乳腺癌患者生存时间的危险因素。

Objective To discuss the relationship between BRCA1 promoter methylation and survival time in patients with breast cancer. Methods Relevant articles on BRCA1 promote methylation in patients with breast cancer published by November 2017 were retrieved from Chinese and English databases including Pub Med and CMB. A metal analysis was performed using Stata 12. 0 software. The combined values were hazard ratio（ HR）and its 95% CI. Results A total of 13 studies involving 3 654 patients were finally included. The result of meta-analysis showed that HR of the overall survival of breast cancer was 1. 91（ 95% CI： 1. 25-2. 57） and,following adjustment for potential confounders,the HR of the overall survival of breast cancer was 1. 50（ 95%CI： 1. 09-1. 90）. HR of the disease free survival of breast cancer was 2. 08（ 95% CI： 1. 48-2. 68） and,following adjustment for potential confounders,HR of the disease free survival of breast cancer was 2. 69（ 95%CI： 0. 39-5. 00）. Conclusion BRCA1 promoter methylation appears to be a prognostic factor for over survival and disease free survival in breast cancer patients.